Sökning: WFRF:(Meyer Klaus) >
DuoMab :
DuoMab : a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity
-
- Sustmann, Claudio (författare)
- Roche Innovat Ctr Munich, LMR, Roche Pharma Res & Early Dev pRED, Penzberg, Germany
-
- Dickopf, Steffen (författare)
- Roche Innovat Ctr Munich, LMR, Roche Pharma Res & Early Dev pRED, Penzberg, Germany
-
- Regula, Jörg T. (författare)
- Roche Innovat Ctr Munich, LMR, Roche Pharma Res & Early Dev pRED, Penzberg, Germany
-
visa fler...
-
- Kettenberger, Hubert (författare)
- Roche Innovat Ctr Munich, LMR, Roche Pharma Res & Early Dev pRED, Penzberg, Germany
-
- Mølhøj, Michael (författare)
- Roche Innovat Ctr Munich, LMR, Roche Pharma Res & Early Dev pRED, Penzberg, Germany
-
- Gassner, Christian (författare)
- Roche Innovat Ctr Munich, LMR, Roche Pharma Res & Early Dev pRED, Penzberg, Germany
-
- Weininger, Diana (författare)
- Roche Innovat Ctr Munich, LMR, Roche Pharma Res & Early Dev pRED, Penzberg, Germany
-
- Fenn, Sebastian (författare)
- Roche Innovat Ctr Munich, LMR, Roche Pharma Res & Early Dev pRED, Penzberg, Germany
-
- Manigold, Tobias (författare)
- Roche Innovat Ctr Basel, Discovery Oncol, Roche Pharma Res & Early Dev pRED, Basel, Switzerland
-
- Kling, Lothar (författare)
- Roche Innovat Ctr Munich, LMR, Roche Pharma Res & Early Dev pRED, Penzberg, Germany
-
- Künkele, Klaus-Peter (författare)
- Roche Innovat Ctr Munich, LMR, Roche Pharma Res & Early Dev pRED, Penzberg, Germany
-
- Schwaiger, Manfred (författare)
- Roche Innovat Ctr Basel, Discovery Oncol, Roche Pharma Res & Early Dev pRED, Basel, Switzerland; Univ Hosp Basel, Dept Rheumatol, Basel, Switzerland
-
- Bossenmaier, Birgit (författare)
- Roche Innovat Ctr Munich, LMR, Roche Pharma Res & Early Dev pRED, Penzberg, Germany
-
- Griese, Julia J. (författare)
- Uppsala universitet,Strukturbiologi,Gene Center and Department of Biochemistry, Ludwig-Maximilians-University, Munich, Germany
-
- Hopfner, Karl-Peter (författare)
- Ludwig Maximilians Univ Munchen, Gene Ctr, Munich, Germany; Ludwig Maximilians Univ Munchen, Dept Biochem, Munich, Germany
-
- Graff-Meyer, Alexandra (författare)
- Univ Basel, Ctr Cellular Imaging & Nanoanalyt, Biozentrum, Basel, Switzerland
-
- Stahlberg, Henning (författare)
- Univ Basel, Ctr Cellular Imaging & Nanoanalyt, Biozentrum, Basel, Switzerland
-
- Ringler, Philippe (författare)
- Univ Basel, Ctr Cellular Imaging & Nanoanalyt, Biozentrum, Basel, Switzerland
-
- Lauer, Matthias E. (författare)
- Roche Innovat Ctr Basel, Small Mol Res, Roche Pharma Res & Early Dev pRED, Basel, Switzerland
-
- Brinkmann, Ulrich (författare)
- Roche Innovat Ctr Munich, LMR, Roche Pharma Res & Early Dev pRED, Penzberg, Germany
-
- Schaefer, Wolfgang (författare)
- Roche Innovat Ctr Munich, LMR, Roche Pharma Res & Early Dev pRED, Penzberg, Germany
-
- Klein, Christian (författare)
- Roche Innovat Ctr Zurich, Discovery Oncol, Roche Pharma Res & Early Dev pRED, Schlieren, Switzerland
-
visa färre...
-
(creator_code:org_t)
- 2019-09-17
- 2019
- Engelska.
-
Ingår i: mAbs. - : Informa UK Limited. - 1942-0862 .- 1942-0870. ; 11:8, s. 1402-1414
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://www.tandfonl...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- High specificity accompanied with the ability to recruit immune cells has made recombinant therapeutic antibodies an integral part of drug development. Here we present a generic approach to generate two novel IgG-derived antibody formats that are based on a modification of the CrossMab technology. MoAbs harbor two heavy chains (HCs) resulting in one binding entity and one fragment crystallizable region (Fc), whereas DuoMabs are composed of four HCs harboring two binding entities and two Fc regions linked at a disulfide-bridged hinge. The latter bivalent format is characterized by avidity-enhanced target cell binding while simultaneously increasing the ‘Fc-load’ on the surface. DuoMabs were shown to be producible in high yield and purity and bind to surface cells with affinities comparable to IgGs. The increased Fc load directed at the surface of target cells by DuoMabs modulates their antibody-dependent cell-mediated cytotoxicity competency toward target cells, making them attractive for applications that require or are modulated by FcR interactions.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)
Nyckelord
- CrossMab
- domain exchange
- cancer therapy
- IGF-1R
- ADCC
- antibody
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
mAbs
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Sustmann, Claudi ...
-
Dickopf, Steffen
-
Regula, Jörg T.
-
Kettenberger, Hu ...
-
Mølhøj, Michael
-
Gassner, Christi ...
-
visa fler...
-
Weininger, Diana
-
Fenn, Sebastian
-
Manigold, Tobias
-
Kling, Lothar
-
Künkele, Klaus-P ...
-
Schwaiger, Manfr ...
-
Bossenmaier, Bir ...
-
Griese, Julia J.
-
Hopfner, Karl-Pe ...
-
Graff-Meyer, Ale ...
-
Stahlberg, Henni ...
-
Ringler, Philipp ...
-
Lauer, Matthias ...
-
Brinkmann, Ulric ...
-
Schaefer, Wolfga ...
-
Klein, Christian
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinsk biotek ...
-
och Medicinsk biotek ...
- Artiklar i publikationen
-
mAbs
- Av lärosätet
-
Uppsala universitet